By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Users of Novo Nordisk’s Wegovy sustain weight loss for 4 years, new analysis shows
News

Users of Novo Nordisk’s Wegovy sustain weight loss for 4 years, new analysis shows

News Room
Last updated: 2024/05/14 at 6:14 AM
By News Room
Share
4 Min Read
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a reduced risk of heart disease regardless of their weight, according to new research that adds evidence to the drug’s broader health benefits.

Two new studies published on Tuesday in Nature Medicine built on Novo Nordisk trial data first published in November, which found that patients using Wegovy had a 20 per cent reduction of risk of heart attacks and other cardiovascular events.

One of the new studies based on the Select trial found that users of the drug over a period of three years and four months sustained their weight loss over four years, in a 17,604-person trial.

Participants in the trial lost on average 10 per cent of their body weight over the four-year period, and 7.7cm from their waist size.

The participants had obesity but not diabetes, and also had a history of cardiovascular diseases. Participants used 2.5mg of semaglutide, the active ingredient in Wegovy and Novo Nordisk’s diabetes drug Ozempic, on a weekly basis.

“This degree of weight loss in such a large and diverse population suggests that it may be possible to impact the public health burden of multiple obesity-related illnesses,” said Professor Donna Ryan, of Pennington Biomedical Research Center in Louisiana, who led the study.

The continued plateauing of weight for users of the drug could support broader use of the treatments by health services, said Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, who was not involved in the study.

The UK health service at present limits availability of the drugs to overweight patients to two years, due in part to limited evidence on long-term cost-effectiveness of the drugs.

“We know that weight regain is very common in patients who stop taking semaglutide after this time but we didn’t [until now] have any safety data or proof that weight would remain off,” said Cork.

A separate analysis of the Novo Nordisk trial led by researchers at University College London and also being presented at the European Congress on Obesity in Venice this week, showed that treatment with semaglutide delivered cardiovascular benefits regardless of the starting weight of trial participants and the weight lost.

Professor John Deanfield, an academic at UCL, said: “Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat.

“These alternative mechanisms may include positive impacts on blood sugar, blood pressure, or inflammation, as well as direct effects on the heart muscle and blood vessels, or a combination of one or more of these,” he said.

Read the full article here

News Room May 14, 2024 May 14, 2024
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Israel-Iran latest: Iran and Israel exchange fresh strikes as conflict escalates

Iran’s Revolutionary Guards have threatened “more forceful and expansive” attacks against Israel…

Bond market braces for potential summer turbulence

Watch full video on YouTube

Has Gap Done The Impossible?

Watch full video on YouTube

Two Alternatives For A Potential $5,000 Monthly Income

This article was written byFollowFinancially Free Investor is a financial writer with…

Thousands protest across US against Trump’s ‘authoritarian’ policies

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

News

Israel-Iran latest: Iran and Israel exchange fresh strikes as conflict escalates

By News Room
News

Two Alternatives For A Potential $5,000 Monthly Income

By News Room
News

Thousands protest across US against Trump’s ‘authoritarian’ policies

By News Room
News

Iran strikes leave Israelis shaken but resolute

By News Room
News

UK moves jets to Middle East after Iran threat

By News Room
News

Donald Trump’s show of military might prompts fears of over-reach

By News Room
News

State lawmaker and husband killed by gunman in Minnesota

By News Room
News

Israel warns ‘Tehran will burn’ as Netanyahu hints at regime change

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?